Fate Therapeutics (FATE) Operating Leases (2019 - 2025)
Historic Operating Leases for Fate Therapeutics (FATE) over the last 7 years, with Q3 2025 value amounting to $74.5 million.
- Fate Therapeutics' Operating Leases fell 1910.3% to $74.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.5 million, marking a year-over-year decrease of 1910.3%. This contributed to the annual value of $77.8 million for FY2024, which is 2004.01% down from last year.
- Per Fate Therapeutics' latest filing, its Operating Leases stood at $74.5 million for Q3 2025, which was down 1910.3% from $75.7 million recorded in Q2 2025.
- Fate Therapeutics' Operating Leases' 5-year high stood at $109.2 million during Q4 2021, with a 5-year trough of $74.5 million in Q3 2025.
- Its 5-year average for Operating Leases is $96.5 million, with a median of $100.6 million in 2023.
- As far as peak fluctuations go, Fate Therapeutics' Operating Leases soared by 4425.87% in 2021, and later plummeted by 2004.01% in 2024.
- Quarter analysis of 5 years shows Fate Therapeutics' Operating Leases stood at $109.2 million in 2021, then fell by 5.06% to $103.7 million in 2022, then decreased by 6.12% to $97.4 million in 2023, then fell by 20.04% to $77.8 million in 2024, then decreased by 4.31% to $74.5 million in 2025.
- Its Operating Leases stands at $74.5 million for Q3 2025, versus $75.7 million for Q2 2025 and $76.8 million for Q1 2025.